Results 21 to 30 of about 17,995 (248)

Assessing the Neurotoxicity of a Sub-Optimal Dose of Rotenone in Zebrafish (Danio rerio) and the Possible Neuroactive Potential of Valproic Acid, Combination of Levodopa and Carbidopa, and Lactic Acid Bacteria Strains

Antioxidants, 2022
Parkinson’s disease (PD) is an enigmatic neurodegenerative disorder that is currently the subject of extensive research approaches aiming at deepening the understanding of its etiopathophysiology.
Ovidiu-Dumitru Ilie, Raluca Duta, Ioana-Miruna Balmus, Alexandra Savuca, Adriana Petrovici, Ilinca-Bianca Nita, Lucian-Mihai Antoci, Roxana Jijie, Cosmin-Teodor Mihai, Alin Ciobica, Mircea Nicoara, Roxana Popescu, Romeo Dobrin, Carmen Solcan, Anca Trifan, Carol Stanciu, Bogdan Doroftei   +16 more
doaj   +1 more source

Reconsidering dopaminergic modulation in Alzheimer's disease: A case for levodopa/carbidopa as a disease-modifying agent. [PDF]

Alzheimers Dement
Nobili A, D'Amelio M.
europepmc   +3 more sources

Preliminary evidence of increased striatal dopamine in a nonhuman primate model of maternal immune activation. [PDF]

, 2019
Women exposed to a variety of viral and bacterial infections during pregnancy have an increased risk of giving birth to a child with autism, schizophrenia or other neurodevelopmental disorders.
Bauman, Melissa D, Carter, Cameron S, Cherry, Simon R, Kukis, David L, Lesh, Tyler A, McAllister, A Kimberley, Rowland, Douglas J, Schumann, Cynthia M, Smucny, Jason   +8 more
core   +2 more sources

Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease

eNeurologicalSci, 2018
We conducted a phase I study investigating the efficacy, safety, and tolerability of ONO-2160, a newly developed levodopa pro-drug, and carbidopa compared with levodopa and carbidopa to stabilize levodopa plasma concentration fluctuations in Japanese ...
Masahiro Nomoto, Masahiro Nagai, Noriko Nishikawa, Rina Ando, Yoshifumi Kagamiishi, Koji Yano, Shigeto Saito, Atsushi Takeda   +7 more
doaj   +1 more source

Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity.

PLoS ONE, 2017
Carbidopa is a drug that blocks conversion of levodopa to dopamine outside of central nervous system (CNS) and thus inhibits unwanted side effects of levodopa on organs located outside of CNS during management of Parkinson's Disease (PD).
Huabin Zhu, Henrique Lemos, Brinda Bhatt, Bianca N Islam, Abhijit Singh, Ashish Gurav, Lei Huang, Darren D Browning, Andrew Mellor, Sadanand Fulzele, Nagendra Singh   +10 more
doaj   +1 more source

L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson’s Disease: A Randomised Study

Parkinson's Disease, 2015
Objectives. To characterize the pharmacokinetic profile of levodopa (L-dopa) and carbidopa after repeated doses of the effervescent tablet of melevodopa/carbidopa (V1512; Sirio) compared with standard-release L-dopa/carbidopa in patients with fluctuating
Fabrizio Stocchi, Laura Vacca, Paola Grassini, Stephen Pawsey, Holly Whale, Stefano Marconi, Margherita Torti   +6 more
doaj   +1 more source

The Effects of Treadmill or Overground Walking Training Program on Gait in Parkinson's Disease [PDF]

, 2013
[Abstract] Background. Gait impairment in Parkinson's disease (PD) patients is characterized by the inability to generate appropriate stride length. Treadmill training has been proposed as a therapeutic tool for PD patients.
Bello, Olalla, Castro, X., Fernández-del-Olmo, Miguel, Giráldez-García, Manuel Avelino, López Alonso, Virginia, Morenilla, Luis, Márquez, Gonzalo, Santos-García, Diego, Sánchez Molina, José-Andrés   +8 more
core   +4 more sources

Combinations of drugs in the Treatment of Obesity

Pharmaceuticals, 2010
Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and ...
Marcio C. Mancini, Maria Edna de Melo, Cintia Cercato, Alfredo Halpern, André M. Faria, Eduardo S. L. Oliveira, Bruno Halpern   +6 more
doaj   +1 more source

Clinical profile of levodopa-carbidopa-entacapone intestinal gel infusion in patients with advanced Parkinson’s disease [PDF]

Folia Medica, 2023
Introduction: Parkinson’s disease in its advanced stage is a progressive condition that can be treated with levodopa. The long-term complications of this treatment are difficult to manage.
Karina A. Atanasova-Ivanova, Sonya Ivanova Hristova-Chakmakova, Ivan G. Milanov   +2 more
doaj   +3 more sources

Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide

Brain and Behavior, 2022
Introduction Levodopa and carbidopa are reported to be degraded by magnesium oxide (MgO), which is often used as a laxative for patients with Parkinson's disease (PD).
Noriyuki Miyaue, Madoka Kubo, Masahiro Nagai   +2 more
doaj   +1 more source